Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed's New Data on Neflamapimod in DLB at CTAD 2024
    CervoMed's New Data on Neflamapimod in DLB at CTAD 2024

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193345/0/en/CervoMed-to-Share-New-Data-on-Neflamapimod-as-a-Treatment-for-Dementia-with-Lewy-Bodies-at-the-18th-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    Cervomed Reports Q3 2025 Financials & Corporate Updates
    Cervomed Reports Q3 2025 Financials & Corporate Updates

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184371/0/en/CervoMed-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    CervoMed Reports Ph2b Data On Neflamapimod In Lewy Body Dementia
    CervoMed Reports Ph2b Data On Neflamapimod In Lewy Body Dementia

    08 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/08/3163184/0/en/CervoMed-Announces-New-Data-from-Phase-2b-Trial-Demonstrating-Neflamapimod-s-Potential-as-a-Treatment-for-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    08 Oct 2025
    Share Share
    CervoMed Showcases Neflamapimod Benefits for Lewy Body Dementia
    CervoMed Showcases Neflamapimod Benefits for Lewy Body Dementia

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151536/0/en/CervoMed-Highlights-Neflamapimod-s-Potential-Benefits-in-Session-on-Dementia-with-Lewy-Bodies-at-the-150th-Annual-American-Neurology-Association-Conference.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    CervoMed: RewinD-LB Trial Shows Neflamapimod Slows Dementia
    CervoMed: RewinD-LB Trial Shows Neflamapimod Slows Dementia

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122322/0/en/CervoMed-Announces-32-Week-Data-from-RewinD-LB-Trial-Extension-Phase-Showing-Neflamapimod-s-Sustained-Effect-on-Slowing-Clinical-Progression-in-Patients-with-Dementia-with-Lewy-Bod.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    CervoMed Announces Presentations at Alzheimer’s Congress 2025
    CervoMed Announces Presentations at Alzheimer’s Congress 2025

    08 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/08/3111598/0/en/CervoMed-Announces-Late-Breaking-Presentations-at-Alzheimer-s-Association-International-Congress-2025.html

    GLOBENEWSWIRE
    08 Jul 2025
    Share Share